We aim to investigate the role of LAP3 in NAFLD pathogenesis and explore whether LAP3 has the potential to be a candidate biomarker in serum for NAFLD diagnosis. The gene discussed is LAP3; the disease is metabolic dysfunction-associated steatotic liver disease.